Drug intelligence / Profile preview

DHNP-D02

Development stage: Preclinical
Lead developer: Daehan Nupharm
Modality: Small Molecules

Overview

DHNP-D02 is a small molecule drug candidate being developed by Daehan Nupharm for the treatment of osteoarthritis in veterinary medicine. It is part of the company's animal health research pipeline, specifically targeting degenerative joint conditions in companion animals. The development aims to provide a therapeutic option for managing pain and improving mobility in animals suffering from joint inflammation. As a pipeline candidate, specific details regarding its pharmacological target or chemical structure remain proprietary to Daehan Nupharm, though it is categorized as a small molecule therapeutic within their animal medicine division.

Beyond the preview

Go deeper on DHNP-D02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHNP-D02.

Explore the full profile